USC-Neurocrine Biosciences
PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM
2021-2022

IN PARTNERSHIP WITH

USC School of Pharmacy
About Neurocrine Biosciences

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis* and uterine fibroids*, with three pivotal and five mid-stage clinical programs in multiple therapeutic areas. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. *in collaboration with AbbVie

About USC School of Pharmacy

The USC School of Pharmacy is the only private pharmacy school on a major health sciences campus, which includes the Keck School of Medicine, Keck Hospital of USC and the USC Norris Comprehensive Cancer Center and is immediately adjacent to the LAC+USC Medical Center, one of the largest public hospitals in the country.

Ranked by US News and World Report as a top ten pharmacy school nationwide and #1 among private schools, the USC School of Pharmacy is recognized for its century-old reputation for innovation in pharmaceutical education, clinical practice, and research. The School uniquely spans the entire spectrum of pharmaceutical development and clinical care – from drug discovery to regulatory approaches that promote safety and innovation, from delivery of patient care services to evaluating the impact of care on patient outcomes and costs.
# Products and Pipeline

<table>
<thead>
<tr>
<th>PROGRAM</th>
<th>THERAPEUTIC AREA</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
<th>NDA</th>
<th>COMMERCIAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ingrezza (valbenazine)*</td>
<td>Tardive Dyskinesia</td>
<td><img src="image1" alt="Phase 1" /></td>
<td><img src="image2" alt="Phase 2" /></td>
<td><img src="image3" alt="Phase 3" /></td>
<td><img src="image4" alt="NDA" /></td>
<td><img src="image5" alt="Commercial" /></td>
</tr>
<tr>
<td>Ongentys (crinecerfont NBI-74768) €</td>
<td>Parkinson’s Disease</td>
<td><img src="image1" alt="Phase 1" /></td>
<td><img src="image2" alt="Phase 2" /></td>
<td><img src="image3" alt="Phase 3" /></td>
<td><img src="image4" alt="NDA" /></td>
<td><img src="image5" alt="Commercial" /></td>
</tr>
<tr>
<td>Orilissa (crinecerfont NBI-74768) †</td>
<td>Endometriosis</td>
<td><img src="image1" alt="Phase 1" /></td>
<td><img src="image2" alt="Phase 2" /></td>
<td><img src="image3" alt="Phase 3" /></td>
<td><img src="image4" alt="NDA" /></td>
<td><img src="image5" alt="Commercial" /></td>
</tr>
<tr>
<td></td>
<td>Uterine Fibroids</td>
<td><img src="image1" alt="Phase 1" /></td>
<td><img src="image2" alt="Phase 2" /></td>
<td><img src="image3" alt="Phase 3" /></td>
<td><img src="image4" alt="NDA" /></td>
<td><img src="image5" alt="Commercial" /></td>
</tr>
<tr>
<td></td>
<td>Chorea in Huntington Disease</td>
<td><img src="image1" alt="Phase 1" /></td>
<td><img src="image2" alt="Phase 2" /></td>
<td><img src="image3" alt="Phase 3" /></td>
<td><img src="image4" alt="NDA" /></td>
<td><img src="image5" alt="Commercial" /></td>
</tr>
<tr>
<td></td>
<td>Congenital Adrenal Hyperplasia (Adult)</td>
<td><img src="image1" alt="Phase 1" /></td>
<td><img src="image2" alt="Phase 2" /></td>
<td><img src="image3" alt="Phase 3" /></td>
<td><img src="image4" alt="NDA" /></td>
<td><img src="image5" alt="Commercial" /></td>
</tr>
<tr>
<td></td>
<td>Congenital Adrenal Hyperplasia (Pediatric)</td>
<td><img src="image1" alt="Phase 1" /></td>
<td><img src="image2" alt="Phase 2" /></td>
<td><img src="image3" alt="Phase 3" /></td>
<td><img src="image4" alt="NDA" /></td>
<td><img src="image5" alt="Commercial" /></td>
</tr>
<tr>
<td>NBlb-1817²</td>
<td>Parkinson’s Disease</td>
<td><img src="image1" alt="Phase 1" /></td>
<td><img src="image2" alt="Phase 2" /></td>
<td><img src="image3" alt="Phase 3" /></td>
<td><img src="image4" alt="NDA" /></td>
<td><img src="image5" alt="Commercial" /></td>
</tr>
<tr>
<td></td>
<td>Polycystic Ovary Syndrome</td>
<td><img src="image1" alt="Phase 1" /></td>
<td><img src="image2" alt="Phase 2" /></td>
<td><img src="image3" alt="Phase 3" /></td>
<td><img src="image4" alt="NDA" /></td>
<td><img src="image5" alt="Commercial" /></td>
</tr>
<tr>
<td>NBI-1065844 (TAK-831)</td>
<td>Negative Symptoms of Schizophrenia</td>
<td><img src="image1" alt="Phase 1" /></td>
<td><img src="image2" alt="Phase 2" /></td>
<td><img src="image3" alt="Phase 3" /></td>
<td><img src="image4" alt="NDA" /></td>
<td><img src="image5" alt="Commercial" /></td>
</tr>
<tr>
<td>NBI-1065845 (TAK-653)</td>
<td>Treatment-Resistant Depression</td>
<td><img src="image1" alt="Phase 1" /></td>
<td><img src="image2" alt="Phase 2" /></td>
<td><img src="image3" alt="Phase 3" /></td>
<td><img src="image4" alt="NDA" /></td>
<td><img src="image5" alt="Commercial" /></td>
</tr>
<tr>
<td>NBI-1065846 (TAK-041)</td>
<td>Anhedonia in Depression</td>
<td><img src="image1" alt="Phase 1" /></td>
<td><img src="image2" alt="Phase 2" /></td>
<td><img src="image3" alt="Phase 3" /></td>
<td><img src="image4" alt="NDA" /></td>
<td><img src="image5" alt="Commercial" /></td>
</tr>
<tr>
<td>NBI-921352</td>
<td>Epilepsy</td>
<td><img src="image1" alt="Phase 1" /></td>
<td><img src="image2" alt="Phase 2" /></td>
<td><img src="image3" alt="Phase 3" /></td>
<td><img src="image4" alt="NDA" /></td>
<td><img src="image5" alt="Commercial" /></td>
</tr>
<tr>
<td>NBI-827104 (ACT-709478)</td>
<td>Epilepsy</td>
<td><img src="image1" alt="Phase 1" /></td>
<td><img src="image2" alt="Phase 2" /></td>
<td><img src="image3" alt="Phase 3" /></td>
<td><img src="image4" alt="NDA" /></td>
<td><img src="image5" alt="Commercial" /></td>
</tr>
</tbody>
</table>

Neurocrine Biosciences has global rights unless otherwise noted.
* Mitsubishi Tanabe Pharma has commercialization rights in East Asia; † Abbvie has global commercialization rights; ‡ Bial retains commercialization rights outside U.S. and Canada; † Voyager Therapeutics has co-commercialization option for U.S. market following the ongoing Phase II RESTORE-1 study; § U.S. commercial launch expected in 2020.
Letter from the Director

Dear Candidates,

As you consider the next chapter in your professional career, we would like to thank you for your interest in exploring our USC-Neurocrine Biosciences Industry Fellowships in Medical Affairs. The growing biopharmaceutical industry provides an incredible opportunity for those looking for a diverse and different profession.

As founders and directors of the fellowship program here at Neurocrine, we are committed to providing experiences that will help shape the future leaders in Medical Affairs. To guide and prepare our fellows for a career in industry, our program offers a wealth of mentorship, diverse training, and numerous opportunities within the core medical functions. Our fellows become part of our team. They will contribute to multidisciplinary groups and building relationships across various departments and functions. Moreover, we have seasoned preceptors and the support of a company committed to its employees and the patients we serve. Our culture of integrity, innovation, inclusiveness, and collaboration creates an atmosphere which promotes amazing opportunities for our employees and fellows. By working together, we are committed to focusing on improving more lives of patients through a strong and expanding pipeline, a growing workforce, supporting our local community, and staying passionate about our science. This is an exciting time at Neurocrine!

Best of luck as you explore the different opportunities available to you, and we strongly encourage you to consider our Fellowship. On behalf of Neurocrine, we wish you much success in finding the program that is the best for you.

Sincerely,

Paul Minne, PharmD
West MSL Director

Khody Farahmand, PharmD
Medical Communications Director
Fellowship Team

2020-2021 Fellow
Kira Aldrich, PharmD
Neurocrine Medical Affairs Fellow 2020-2021
University of Maryland, Baltimore Class of 2020

“The Neurocrine Medical Affairs fellowship gives me the training and opportunity to develop my interest in Medical Affairs and neuroscience into a career. Here, I have the structure and flexibility to pursue a custom learning experience within Medical Affairs and cross-functionally. With the support of my mentors, I’m able to make meaningful contributions to the team, and explore unique opportunities as the fellowship progresses.”

Fellowship Mentor
Katie Moy, PharmD
Manager, Medical Communications
Neurocrine Biosciences

Katie Moy is the Medical Communications Content Lead for Parkinson’s disease within Medical Affairs. In this role she leads the strategic development and execution of medical communications and medical information content for the Parkinson’s disease portfolio. She has managed direct reports, student interns, and our current fellow. Before joining Neurocrine, Katie worked at Amgen supporting the US and Global Medical Communications teams, eventually leading Global Medical Information for Prolia and the launch of EVENITY. In these roles, she was responsible for development of medical information and medical liaison resources, digital disease state education content, advisory board planning and execution, management of complex medical inquiry escalations, and scientific review of promotional materials. Katie completed her Post-Doctoral Fellowship in Medical Information at Baxter Healthcare, supporting the Immunology portfolio. She earned her PharmD from the University of California, San Diego.

Fellowship Mentor
Diane Darling, PharmD
Senior Medical Science Liaison
Neurocrine Biosciences

Diane Darling joined the Neurocrine MSL team in 2017, supporting the Ohio Valley Region. Prior to Neurocrine, Diane spent 15 years in the pharmaceutical industry at AstraZeneca, Boehringer-Ingelheim, and Tardis Medical Consultancy. She has worked in a variety of therapeutic areas including CNS, cardiology and pulmonology with many product launches. Diane received her BS in Pharmacy from The Ohio State University and her PharmD from University of Florida. She recently became a Board-Certified Geriatric Pharmacist (BCGP). She has worked extensively in geriatrics and long-term care as a consultant pharmacist, consultant manager and pharmacist-in-charge of operations. She is active in the American Society of Consultant Pharmacists and served on the Board of Directors for the Midwest. Diane is a licensed pharmacist and has lectured several colleges of pharmacy.

USC Director
William C. Gong, PharmD, FASHP, FCSHP
Director, Residency Fellowship Programs
University of Southern California, School of Pharmacy
Medical Affairs Fellowship

The one-year Medical Affairs Fellowship is designed to provide the trainee a broad understanding of the various roles and responsibilities within Medical Affairs. The fellowship will provide training activities that support company goals; as well as developmental opportunities through broad-based hands-on experiences and mentorships that integrate them into several medical strategic initiatives. Upon completion of the program, the Fellow will be better prepared for the challenges of a Medical Affairs career in the pharmaceutical industry.

Fellowship Objectives

- Train as a member of the Medical Affairs team to gain insight into the various roles within Medical Affairs and other functional groups.
- Rotate through a number of core Medical functions with the opportunity to contribute to multidisciplinary teams and build relationships across departments and functions (e.g., health economics and outcomes research, regulatory, market access, clinical development, marketing, and compliance).
  - Medical Information/Medical Communications: Assist in providing accurate, fair-balanced, evidence-based information about Neurocrine-approved and pipeline products to internal stakeholders and external customers.
  - Publications: Train in cross-functional teams to assist with the execution of the strategic publication plans.
  - Medical Training: Collaborate with key internal stakeholders to support the development of educational materials based on Neurocrine therapies and disease states.
  - Field Medical: Support the field medical team through various activities, training, and initiatives that are strategically aligned with key opinion leader (KOL) priorities. Gain Medical Science Liaison field experience.
- Identify medical team needs and data gaps and collaborate internally to help drive appropriate solutions and projects.
- Develop, implement, and present a longitudinal research project.
- Serve as a rotation preceptor to pharmacy students.
- Collaborate with the USC-Neurocrine Field Medical Affairs co-fellow.
- Complete required graduate coursework at the University of Southern California with the opportunity to complete a Certificate in Regulatory Sciences.
- Participate in the University of Southern California, School of Pharmacy Professional Development and Leadership Retreat.
Field Medical Affairs/MSL Fellowship

The one-year Field Medical Affairs/Medical Science Liaison (MSL) Fellowship is designed to provide the trainee with a comprehensive understanding of the MSL role and insight into the various roles within Medical Affairs. The fellowship will provide training activities that support company goals as well as developmental opportunities through broad-based hands-on experiences and mentorships that integrate them into several Medical Affairs strategic initiatives. Upon completion of the program, the Fellow will be better prepared for the challenges of an MSL career in the pharmaceutical industry.

Fellowship Objectives

- Gain Medical Science Liaison experience and training in the field by learning to build collaborative KOL relationships, effective communication skills, participate in scientific data exchange, and apply the medical strategy during real life HCP interactions.
- Collaborate with key cross-functional internal partners with Neurocrine including the Managed Care Liaisons, Medical Communications, Medical Information, Health Economics Outcomes Research, medical directors, clinical development, compliance, regulatory, and marketing.
- Participate in MSL certification and presentation skill development.
- Train as a core member of the Field Medical Affairs team to assist in providing accurate, fair-balanced, evidence-based information about Neurocrine approved and pipeline products to internal stakeholders and external customers.
- Identify medical team needs and data gaps and collaborate internally to help drive appropriate solutions and projects.
- Support the product speakers’ bureaus.
- Understanding of research initiatives through active participation in site nominations, study initiation visits, data dissemination, and the Investigator Initiated Trial (IIT) process.
- Develop, implement, and present a longitudinal research project.
- Serve as a rotation preceptor to pharmacy students.
- Collaborate with the USC-Neurocrine Medical Affairs co-fellow.
- Complete required graduate coursework at the University of Southern California with the opportunity to complete a Certificate in Regulatory Sciences.
- Participate in the University of Southern California, School of Pharmacy Professional Development and Leadership Retreat.
Application Requirements

• PharmD, MD, or PhD in applicable field from an accredited university
• Good oral and written communication skills, ethics, professionalism, leadership and an interest in the biopharmaceutical industry

Application Process

• The application for the 2021-2022 cycle will be available on October 1, 2020.
• The USC Postdoctoral Fellowship Portal can be accessed online at https://resfellow.smapply.io/prog/fellowship/, where you will be asked to submit the following:
  • Curriculum Vitae
  • Letter of Intent
  • Email addresses of three references
  • Official pharmacy school or graduate school transcripts
• The USC Postdoctoral Fellowship Portal application is due by December 11, 2020.

Interview Process

Please submit a Curriculum Vitae and Letter of Intent through the Personal Placement Service (PPS) to request a first-round interview.

Final interviews will be conducted at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting, which will take place virtually December 6-10.